- Previous Close
1.0000 - Open
1.0120 - Bid 1.0000 x --
- Ask 1.0400 x --
- Day's Range
0.9850 - 1.0200 - 52 Week Range
0.6750 - 1.3400 - Volume
60,366 - Avg. Volume
55,078 - Market Cap (intraday)
154.544M - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.40
Trajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company offers analytical products, including syringes, GC columns and septa, rings, inlet liners, and tubing products; pathology products, consisting of NBF containers, adhesive and frosted microscope slides, coverslips, slide storage trays/mailers, cassette storage boxes, biopsy pads, histology wax plus, microtome blades, and marking dyes and sets, and MiPlatform, a smartphone adapter. It also provides sampling products, comprising septa, caps, liners, crimping tools, well plates and sealing mats, and micro sampling tools, as well as automation systems for the analysis of biological, food, and environmental samples. The company was incorporated in 2011 and is headquartered in Ringwood, Australia.
www.trajanscimed.comRecent News: TRJ.AX
View MorePerformance Overview: TRJ.AX
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRJ.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRJ.AX
View MoreValuation Measures
Market Cap
154.54M
Enterprise Value
199.46M
Trailing P/E
--
Forward P/E
144.93
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.00
Price/Book (mrq)
1.50
Enterprise Value/Revenue
1.29
Enterprise Value/EBITDA
21.80
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.34%
Return on Assets (ttm)
0.08%
Return on Equity (ttm)
-21.80%
Revenue (ttm)
155.02M
Net Income Avi to Common (ttm)
-25.33M
Diluted EPS (ttm)
-0.1700
Balance Sheet and Cash Flow
Total Cash (mrq)
11.24M
Total Debt/Equity (mrq)
54.61%
Levered Free Cash Flow (ttm)
11.06M